Intech Investment Management LLC Acquires 174,403 Shares of Zoetis Inc. $ZTS

Intech Investment Management LLC boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 2,134.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 182,575 shares of the company’s stock after buying an additional 174,403 shares during the period. Intech Investment Management LLC’s holdings in Zoetis were worth $26,714,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in ZTS. North Star Asset Management Inc. raised its stake in shares of Zoetis by 4.9% during the 2nd quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock valued at $225,000 after purchasing an additional 67 shares during the period. Bank of Nova Scotia Trust Co. grew its holdings in Zoetis by 4.6% during the 2nd quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company’s stock valued at $264,000 after buying an additional 74 shares in the last quarter. RWA Wealth Partners LLC increased its position in shares of Zoetis by 2.7% during the second quarter. RWA Wealth Partners LLC now owns 2,852 shares of the company’s stock valued at $445,000 after buying an additional 76 shares during the period. Summit Place Financial Advisors LLC increased its position in shares of Zoetis by 0.4% during the third quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock valued at $2,834,000 after buying an additional 76 shares during the period. Finally, GPS Wealth Strategies Group LLC lifted its holdings in shares of Zoetis by 20.2% in the second quarter. GPS Wealth Strategies Group LLC now owns 465 shares of the company’s stock worth $72,000 after buying an additional 78 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.4%

Shares of ZTS stock opened at $129.15 on Thursday. The business has a 50-day moving average price of $125.74 and a two-hundred day moving average price of $134.31. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.00. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The firm has a market cap of $54.52 billion, a P/E ratio of 21.45, a price-to-earnings-growth ratio of 1.97 and a beta of 0.96.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the company earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.6%. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ZTS. Stifel Nicolaus lowered their target price on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research note on Tuesday, November 18th. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a report on Monday, December 15th. KeyCorp began coverage on Zoetis in a research note on Thursday, November 20th. They set a “sector weight” rating for the company. JPMorgan Chase & Co. decreased their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Finally, Bank of America raised their price target on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. Five equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Zoetis presently has an average rating of “Hold” and an average target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.